Letter · 24 Apr 2013
Conference abstractPublished 23 Sep 2013
How long should adjuvant chemotherapy be given?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Adjuvant chemotherapy is used to reduce the probability of metastatic relapse. This is a very common therapy in oncology- used for almost all early stage breast and colon cancer patients of whom there will be 374,000 in 2013 in US. This therapy is not very effective since 91,000 patients will die of breast and colon cancer in 2013. Despite being used for decades, much work is needed to understand bioequivalence, bioavailability, biosimilars and biowaivers in medical oncology. In May 2011, the author discussed his personal use of low dose long term adjuvant chemotherapy for stage IIIc colon cancer in 1994-1996. This therapy is now known as metronomic chemotherapy. The question the author would like to raise now is: how long should adjuvant chemotherapy is used? If we assume first that cancer growth is well behaved i.e., all cancer cells in the tumor divide once and only once during a doubling time, and second that the chemotherapy drug used is 100% effective, i.e., it kills every cell that tries to divide, then therapy duration should be one doubling time. In the case of colon cancer it is 2-3 months. Based on his estimates of tumor behavior and drug (5-Fluorouracil), he calculated chemotherapy should ideally be used longer than 2 years so he used low dose therapy for 2.5 years. Nobody could tolerate a toxic protocol for over 2 years. In order to be effective for all or nearly all cases, adjuvant chemotherapy must be nontoxic and tolerable for over 2 years.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 2021
Neoadjuvant Chemotherapy is Given Prior Local Treatment Such as Surgery, and is Designed to Shrink the Primary Tumor.
Short communication · 2020
Neoadjuvant Chemotherapy is Given Prior to a Local Treatment Such as Surgery, and is Designed to Shrink the Primary Tumor
Article · 3 Jul 2026
The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyrimidine Monotherapy to Oxaliplatin-Based Regimens
Research article · 18 Aug 2025
Response Evaluation to Oxaliplatin-Based Adjuvant Chemotherapy after Curative Resection between Right and Left-Sided Stage II and III Colon Cancer: A Retrospective Survival Analysis
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Michael Retsky”

